Journals / Bezmiâlem Science / 2019 / Cilt: 7 - Sayı: 3

Management of Patients Using Oral Anticoagulant Agent in Dental Practice

Diş Hekimliği Pratiğinde Oral Antikoagülan Ajan Kullanan Hastalara Yaklaşım

Pages
240–244
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

This review outlines the various properties of the oral anticoagulants and the most recent recommendations and guidelines regarding the management of dental patients taking these medications.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:An increasing number of patients in our country use oral anticoagulants for the prophylaxis and treatment of thromboembolic events.
📊
Key Findings & Data:The cornerstone of these groups of agents is warfarin, a vitamin K antagonist, which has been the single alternative used by oral route for several years.
💡
Conclusion & Impact:This review outlines the various properties of the oral anticoagulants and the most recent recommendations and guidelines regarding the management of dental patients taking these medications.
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

An increasing number of patients in our country use oral anticoagulants for the prophylaxis and treatment of thromboembolic events. The cornerstone of these groups of agents is warfarin, a vitamin K antagonist, which has been the single alternative used by oral route for several years. However, due to warfarin’s late onset and long lasting action and the intense interactions with food and drugs, newer oral anticoagulants have emerged in the market in recent years. Dabigatran, rivaroxaban and apixaban are the novel agents used in our country. Those drugs should be regulated in the perioperative period when patients receiving oral anticoagulants are referred for dental interventions. The interruption of agents may result in lethal consequences of thromboembolic events, while continuing raises the risk of bleeding. This review outlines the various properties of the oral anticoagulants and the most recent recommendations and guidelines regarding the management of dental patients taking these medications.

Özet

Ülkemizde giderek artan sayıda hasta tromboemboli profilaksisi ve tedavisi amacıyla oral antikoagülan ajanlar kullanmaktadır. Bu grup ajanların temel taşı vitamin K antagonisti olan varfarin olup uzun yıllar tromboembolik olaylarda oral yoldan kullanılan tek seçenek olmuştur. Ancak, uzun ve geç başlayan etkisi gıda ve ilaçlarla olan yoğun etkileşimi nedeniyle son yıllarda piyasaya farklı oral antikoagülanlar çıkmıştır. Dabigatran, rivaroksaban ve apiksaban ülkemizde kullanılan yeni nesil oral antikoagülan ajanlardır. Oral antikoagülan kullanan hastaların tedavi protokolünün dental girişimler öncesinde belirlenmesi gerekmektedir. Ajanların kesilmesi tromboembolik olayların ölümcül olabilecek sonuçlarını, devam edilmesi ise kanama riskini gündeme getirmektedir. Bu derleme, oral antikoagülan ajanların çeşitli özelliklerini ve bu ilaçları kullanan hastalara dental girişimlerdeki tedavi yaklaşımını en güncel öneri ve kılavuzlar eşliğinde ele almaktadır.

🔖

Cite This Article

DOĞANAY, Ö. (2019). Management of Patients Using Oral Anticoagulant Agent in Dental Practice. Bezmiâlem Science, Cilt: 7 - Sayı: 3, 240–244. https://ajindex.com/articles/148155

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (10)

  1. http://www.sdcep.org.uk/wp-content/uploads/2015/09/SDCEP-Anticoagulants-Guidance.pdf http://www.sigwales.org/wp-content/uploads/dental-management-of-patients-taking-anticoagulant-drugs-outside-a-general-hospital-setting.pdf
  2. Siegal D, Yudin J, Kaatz S, Douketis JD, Lim W, Spyropoulos AC. Periprocedural heparin bridging in patients receiving vitamin K antagonists: systematic review and meta-analysis of bleeding and thromboembolic rates. Circulation 2012;126:1630-9.
  3. Douketis JD, Healey JS, Brueckmann M, Eikelboom JW, Ezekowitz MD, Fraessdorf M, et al. Perioperative bridging anticoagulation during dabigatran or warfarin interruption among patients who had an elective surgery or procedure. Substudy of the RELY trial. Thromb Haemost 2015;113:625-32.
  4. Steinberg BA, Peterson ED, Kim S, Thomas L, Gersh BJ, Fonarow GC, et al. Outcomes Registry for Better Informed Treatment of Atrial Fibrillation Investigators and Patients. Use and outcomes associated with bridging during anticoagulation interruptionsin patients with atrial fibrillation: findings from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF). Circulation 2015;131:488-94.
  5. Rechenmacher SJ, Fang JC. Bridging Anticoagulation: Primum Non Nocere. J Am Coll Cardiol 2015;66:1392-403.
  6. Beyer-Westendorf J, Gelbricht V, Förster K, Ebertz F, Köhler C, Werth S, et al. Peri-interventional management of novel oral anticoagulants in daily care: results from the prospective Dresden NOAC registry. Eur Heart J 2014;35:1888-96.
  7. Douketis JD, Spyropoulos AC, Kaatz S, Becker RC, Caprini JA, Dunn AS, et al. Perioperative Bridging Anticoagulation in Patients with Atrial Fibrillation. N Engl J Med 2015;373:823-33.
  8. Firriolo FJ, Hupp WS. Beyond warfarin: the new generation of oral anticoagulants and their implicationsfor the management of dental patients. Oral Surg Oral Med Oral Pathol Oral Radiol 2012;113:431-41.
  9. Elad S, Marshall J, Meyerowitz C, Connolly G. Novel anticoagulants: general overview and practical considerations for dental practitioners. Oral Dis 2016;22:23-32. Little JW. New oral anticoagulants: will they replace warfarin? Oral Surg Oral Med Oral Pathol Oral Radiol 2012;113:575-80.
  10. Breuer G, Weiss DR, Ringwald J. ‘New’ direct oral anticoagulants in the perioperative setting. Curr Opin Anaesthesiol 2014;27:409-19. Hong CH and Intekhab I. Anti-Thrombotic Therapy: Implications for Invasive Outpatient Procedures in Dentistry. J Blood Disorders Transf 2013, 4:6. http://dx.doi.org/10.4172/2155